UTSW researchers develop blood test to predict liver cancer risk

Pangea Biomed, OHSU Knight Cancer Institute collaborate to improve cancer therapy precision

Pangea Biomed, a startup developing the Enlight cancer response prediction platform, announced the beginning of a pilot collaboration with the Knight Cancer Institute at Oregon Health and Science University.

November 01, 2024

Vol.50 No.41

Clinical Roundup

Research shows applications of novel cfDNA approach in precision medicine

Research published in Communications Biology demonstrates the potential of Aqtual’s proprietary platform that evaluates gene regulation, epigenetics, and transcriptomics by analyzing previously unexplored cfDNA fragments found in blood, opening the door to novel clinical applications in almost every major disease area.

September 13, 2024

Vol.50 No.34

Clinical Roundup

Kidney cancers rely on mitochondrial metabolism to metastasize, UTSW study shows

Research from Children’s Medical Center Research Institute at UT Southwestern shows that metastatic kidney cancers rely heavily on mitochondrial metabolism. These findings are contrary to how tumors operate while still in the kidney.

September 06, 2024

Vol.50 No.33

Clinical Roundup

UTSW study reveals widespread disparities in immunotherapy use for patients with advanced kidney and bladder cancers

A study led by researchers at UT Southwestern Medical Center reveals significant disparities across the country in the use of immunotherapy for patients with advanced kidney and bladder cancers.

September 06, 2024

Vol.50 No.33

Clinical Roundup

Liver cancer growth tied to tryptophan intake in mice

Researchers at UT Southwestern Medical Center have discovered that a diet free of the amino acid tryptophan can effectively halt the growth of liver cancer in mice. Their findings, published in Nature Communications, offer new insights for dietary-based cancer treatments and highlight the critical role of the tryptophan metabolite indole 3-pyruvate (I3P) in liver tumor development.

August 02, 2024

Vol.50 No.31

Clinical Roundup

Modifying, deleting, or degrading protein ZFP574 reduces division of malignant B cells in lab

Targeting a protein called ZFP574 suppressed leukemia in a mouse model of the disease, UT Southwestern Medical Center researchers showed in a new study. Their findings, published in PNAS, could lead to new treatments for leukemias and lymphomas in cancer patients.

August 02, 2024

Vol.50 No.31

UTSW researchers develop blood test to predict liver cancer risk

YOU MAY BE INTERESTED IN

Pangea Biomed, OHSU Knight Cancer Institute collaborate to improve cancer therapy precision

Research shows applications of novel cfDNA approach in precision medicine

Kidney cancers rely on mitochondrial metabolism to metastasize, UTSW study shows

UTSW study reveals widespread disparities in immunotherapy use for patients with advanced kidney and bladder cancers

Liver cancer growth tied to tryptophan intake in mice

Modifying, deleting, or degrading protein ZFP574 reduces division of malignant B cells in lab

Renew today!

Subscriber content

Login